SEC Company Response from Lyra Therapeutics, Inc. (LYRA) (CIK 0001327273) (LYRA) — Apr 27, 2020
Lyra Therapeutics, Inc. (LYRA) (CIK 0001327273)
Date: April 27, 2020 · CIK: 0001327273 · Accession: 0001193125-20-120347
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-236962
Referenced dates: December 4, 2019
Letter
VIA EDGAR AND OVERNIGHT DELIVERY Office of Healthcare and Insurance United States Securities and Exchange Commission Re: Lyra Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed April 27, 2020 File No. 333-236962
Dear Mr. Fischer:
On behalf of Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), we are transmitting this letter in response to comments received from the staff (the “Staff”) of the Securities and Exchange Commission by letter dated December 4, 2019 with respect to the Company’s Confidential Draft Registration Statement on Form S-1 submitted on November 8, 2019. This letter is being submitted together with a complete copy of the Company’s filed Amendment No. 1 (“Amendment No. 1”) to the Registration Statement on Form S-1 (File No. 333-236962) (as amended, the “Registration Statement”), which has been revised to address the Staff’s comments. The bold and numbered paragraph below corresponds to the numbered paragraph in the Staff’s letter referred to above and is followed by the Company’s response. For the Staff’s convenience, we are also sending, by courier, copies of this letter and marked copies of Amendment No. 1 that reflect changes made to the Registration Statement. Unless otherwise indicated, capitalized terms used herein have the meanings assigned to them in the Registration Statement.
April 27, 2020
Page
Use of Proceeds, page 76
6. Please revise paragraph three to provide an estimate regarding how far in the development process for LYR-210 and LYR-220 the allocated proceeds of the offering will enable you to reach. Please also disclose whether additional funds will be necessary to complete the two trials you identify. If a material amount of other funds is necessary to complete these trials, state the amounts and sources of such other funds. Refer to Instruction 3 of Item 504 of Regulation S-K.
Response: The Company respectfully acknowledges the Staff’s comment and in response has revised the disclosure on page 81 of Amendment No. 1.
April 27, 2020
Page
We hope that the foregoing has been responsive to the Staff’s comments and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact me at 617-948-6027 or Peter Handrinos at 617-948-6060 with any questions or further comments you may have regarding this filing or if you wish to discuss the above.
Sincerely,
/s/ Wesley C. Holmes
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 27, 2020 VIA EDGAR AND OVERNIGHT DELIVERY Mr. Paul Fischer Office of Healthcare and Insurance United States Securities and Exchange Commission 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Re: Lyra Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed April 27, 2020 File No. 333-236962 Dear Mr. Fischer: On behalf of Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), we are transmitting this letter in response to comments received from the staff (the “Staff”) of the Securities and Exchange Commission by letter dated December 4, 2019 with respect to the Company’s Confidential Draft Registration Statement on Form S-1 submitted on November 8, 2019. This letter is being submitted together with a complete copy of the Company’s filed Amendment No. 1 (“Amendment No. 1”) to the Registration Statement on Form S-1 (File No. 333-236962) (as amended, the “Registration Statement”), which has been revised to address the Staff’s comments. The bold and numbered paragraph below corresponds to the numbered paragraph in the Staff’s letter referred to above and is followed by the Company’s response. For the Staff’s convenience, we are also sending, by courier, copies of this letter and marked copies of Amendment No. 1 that reflect changes made to the Registration Statement. Unless otherwise indicated, capitalized terms used herein have the meanings assigned to them in the Registration Statement. April 27, 2020 Page 2 Use of Proceeds, page 76 6. Please revise paragraph three to provide an estimate regarding how far in the development process for LYR-210 and LYR-220 the allocated proceeds of the offering will enable you to reach. Please also disclose whether additional funds will be necessary to complete the two trials you identify. If a material amount of other funds is necessary to complete these trials, state the amounts and sources of such other funds. Refer to Instruction 3 of Item 504 of Regulation S-K. Response: The Company respectfully acknowledges the Staff’s comment and in response has revised the disclosure on page 81 of Amendment No. 1. April 27, 2020 Page 3 We hope that the foregoing has been responsive to the Staff’s comments and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact me at 617-948-6027 or Peter Handrinos at 617-948-6060 with any questions or further comments you may have regarding this filing or if you wish to discuss the above. Sincerely, /s/ Wesley C. Holmes Wesley C. Holmes of LATHAM & WATKINS LLP Enclosures cc: (via e-mail) Maria Palasis, Chief Executive Officer, Lyra Therapeutics, Inc. Peter N. Handrinos, Latham & Watkins LLP